Late relapse of testis cancer

Current Urology Reports

Volumn 14, Issue 5, 2013, Pages 518-524

  Ehrlich, Yaron ^a,b   Rosenbaum, Eli ^a,b   Baniel, Jack ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Follow up; Germ cell tumor; Late relapse; Lymph node dissection; Malignant transformation; Recurrence; Retroperitoneum; Seminoma; Teratoma; Testis; Yolk sack tumor

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; PACLITAXEL;

ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; ECHOGRAPHY; GENE EXPRESSION PROFILING; GENE MUTATION; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RECURRENT CANCER; RETROPERITONEUM; RISK FACTOR; SALVAGE THERAPY; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTIS CANCER;

COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; MALE; NEOPLASM RECURRENCE, LOCAL; TESTICULAR NEOPLASMS; TIME FACTORS; WORLD HEALTH;

EID: 84886793544     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0355-4     Document Type: Article

References (60)

1. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1981;41(9 Pt 1):3275-80.
2. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337(4):242-53.
3. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435-40.
4. Bosl GJ, Gluckman R, Geller NL, et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol. 1986;4(10):1493-9.
5. Lipphardt ME, Albers P. Late relapse of testicular cancer. World J Urol. 2004;22(1):47-54.
6. •• Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol. 1995;13(5):1170-6. Indiana University was the first to report late relapse as a distinct clinical entity.
7. Odell WD, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med. 1987;317:1688-91.
8. Stenman UH, Alfthan H, Ranta T, Vartiainen E, Jalkanen J, Seppala M. Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab. 1987;64:730-6.
9. Catalona WJ, Vaitukaitis JL, Fair WR. Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumors: conversion to negative with testosterone administration. J Urol. 1979;122:126-8.
10. Garnick MB. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N Engl J Med. 1980;303:1177.
11. Braunstein GD, Thompson R, Gross S, Soares JR. Marijuana use does not spuriously elevate serum human chorionic gonadotropin levels. Urology. 1985;25:605-6.
12. Bell H. Alpha-fetoprotein and carcinoembryonic antigen in patients with primary liver carcinoma, metastatic liver disease, and alcoholic liver disease. Scand J Gastroenterol. 1982;17:897-903.
13. Waldmann TA, McIntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer. 1974;34(suppl):1510-5.
14. Masopust J, Kithier K, Rádl J, Koutecký J, Kotál L. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer. 1968;3:364-73.
15. Kitau MJ, Grint PC, Heath RB, Chard T. Serum alphafetoprotein levels in subjects infected with hepatitis B virus. J Med Virol. 1988;26:437-42.
16. Schefer H, Mattmann S, Joss RA. Hereditary persistence of alpha-fetoprotein. Case report and review of the literature. Ann Oncol. 1998;9:667-72.
17. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23(28):6999-7004.
18. George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003;21(1):113-22.
19. Mukhtar S, Beatty J, Agrawal S, et al. Germ cell tumour: late recurrence after 43 years. Ann R Coll Surg Engl. 2011;93:e24-6.
20. • Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;173(3):824-9. A contemporary population based study of late relapse.
21. Oldenburg J, Alfsen GC, Waehre H, et al. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer. 2006;94:820-7.
22. Oldenburg J, Martin JM, Fosså SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol. 2006;24:5503-11.
23. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol. 1997;8(1):41-7.
24. Ravi R, Oliver RT, Ong J, et al. A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol. 1997;80(4):647-52.
25. Kuczyk MA, Bokemeyer C, Kollmannsberger C, et al. Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center based experience. World J Urol. 2004;22(1):55-9.
26. Michael H, Lucia J, Foster RS, et al. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol. 2000;24(2):257-73.
27. Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 2002;95(3):520-30.
28. Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878-88.
29. Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol. 2011;29:719-25.
30. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200-8.
31. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146-54.
32. Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103:241-9.
33. Kollmannsberger C, Moore C, Chi KN, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. 2010;21:1296-301.
34. Sturgeon JF, Moore MJ, Kakiashvili DM, et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol. 2011;59:556-62.
35. Nolan L, Wheater M, Kirby J, et al. Late relapse (>2 years) on surveillance in stage I non-seminomatous germ cell tumours; predominant seminoma only histology. BJU Int. 2010;106:1648-51.
36. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27:2122-8.
37. Nicolai N, Miceli R, Necchi A, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol. 2010;58:912-8.
38. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005;23(36):9290-4.
39. Ehrlich Y, Beck SDW, Ulbright TM, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol. 2010;21:1846-50.
40. Loehrer Sr PJ, Hui S, Clark S, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986;135(6):1183-9.
41. Leibovitch I, Foster RS, Ulbright TM, et al. Adult primary pure teratoma of the testis. The Indiana experience. Cancer. 1995;75:2244-50.
42. Kernek KM, Ulbright TM, Zhang S, et al. Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol. 2003;163:2477-84.
43. van Echten J, van der Vloedt WS, van de Pol M, et al. Comparison of the chromosomal pattern of primary testicular nonseminomas and residual mature teratomas after chemotherapy. Cancer Genet Cytogenet. 1997;99:59-67.
44. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study group. J Clin Oncol. 2001;19(10):2647-57.
45. Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998;82(7):1343-51.
46. Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: Results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668-76.
47. Debono DJ, Heilman DK, Einhorn LH, et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15:1455-64.
48. Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. J Clin Oncol. 2010;28:519-2.
49. Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a post-chemotherapy retroperitoneal lymph node dissection needed following complete remission? J Clin Oncol. 2010;28:531-6.
50. •• Sharp DS, Carver BS, Eggener SE, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008;26:5524-9. Contemporary late relapse series from MSKCC emphasizing the importance of complete surgical excision of late relapse masses.
51. Schmoll HJ. SouchonR, Krege S, et al.: European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15(9):1377-99.
52. Geldart TR, Gale J, McKendrick J, et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int. 2006;98:353-8.
53. •• Lorch A, Rick O, Wündisch T, et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol. 2010;184:168-73. Late relapse not suitable for surgery is chemoresistant and response to high dose chemotherapy is usually not durable.
54. Aparicio J. Garcia del Muro X, Maroto P, et al.: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol. 2003;14(6):867-72.
55. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293-300.
56. Muramaki M, Hara I, Miyake H, et al. Clinical study of six cases showing late relapse of germ cell tumors. Int J Urol. 2005;12(9):855-8.
57. Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998;58(19):4260-3.
58. Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003;14(6):873-80.
59. Mayer F, Wermann H, Albers P, et al. Histopathological and molecular features of late relapses in non-seminomas. BJU Int. 2011;107:936-43.
60. Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res. 2004;10(7):2368-78.